Revista Española de Cardiología (English Edition) Revista Española de Cardiología (English Edition)
Rev Esp Cardiol. 2018;71:538-44 - Vol. 71 Num.07 DOI: 10.1016/j.rec.2017.10.009

Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y 12 Inhibitors in Patients With Acute Coronary Syndrome

Pedro J. Flores-Blanco a,, Francisco Cambronero-Sánchez b, Sergio Raposeiras-Roubin c, Emad Abu-Assi c, Gunnar Leithold a, Rafael Cobas-Paz c, Ana I. Rodríguez Serrano a, Francisco Calvo-Iglesias c, Mariano Valdés a,d, James L. Januzzi e, Andrés Iñiguez-Romo c, Sergio Manzano-Fernández a,d

a Departamento de Medicina Interna, Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria, El Palmar, Murcia, Spain
b Departamento de Medicina Interna, Servicio de Cardiología, Hospital General Universitario Los Arcos del Mar Menor, San Javier, Murcia, Spain
c Departamento de Cardiología, Hospital Universitario Álvaro Cunqueiro de Vigo, Vigo, Pontevedra, Spain
d Departamento de Medicina Interna, Facultad de Medicina, Universidad de Murcia, Murcia, Spain
e Division of Cardiology, Massachusetts General Hospital, Boston, United States

Keywords

GRACE. CRUSADE. Prasugrel. Ticagrelor and acute coronary syndromes.

Abstract

Introduction and objectives

Acute coronary syndrome (ACS) guidelines recommend the use of newer P2Y12 inhibitors (prasugrel and ticagrelor) over clopidogrel in patients with moderate-to-high ischemic risk, unless they have an increased bleeding risk. The aim of our study was to assess the GRACE risk score and the CRUSADE bleeding risk score relative to prescription of newer P2Y12 inhibitors at discharge in ACS patients.

Methods

Retrospective analysis of a multicenter ACS registry; 3515 consecutive patients were included. The association between risk scores and prescription of newer P2Y12 inhibitors was assessed by binary logistic regression analysis.

Results

A total of 1021 patients (29%) were treated with prasugrel or ticagrelor. On multivariate analyses, both GRACE (OR per 10 points, 0.89; 95%CI, 0.86-0.92; P < .001) and CRUSADE (OR per 10 points, 0.96; 95%CI, 0.94-0.98; P < .001) risk scores were inversely associated with the use of newer P2Y12 inhibitors. Moreover, other factors not included in these scores (revascularization approach, in-hospital stent thrombosis, major bleeding, and concomitant indication for anticoagulation therapy) also predicted the use of newer P2Y12 inhibitors.

Conclusions

New P2Y12 inhibitors were more frequently prescribed among ACS patients with lower CRUSADE bleeding risk. However, an ischemic risk paradox was found, with higher use of these agents in patients with lower ischemic risk based on GRACE risk score estimates. These results underscore the importance of risk stratification to safely deliver optimal therapies.

1885-5857/© 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved

Cookies
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
Cookies policy
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.